New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
14:01 EDTPTCTPTC Therapeutics announces expanded access program for Translarna
PTC Therapeutics announced the initiation of a reimbursed expanded access program, or EAP. PTC's EAP program is intended to make Translarna available to patients before commercial availability in certain countries. Where mechanisms exist and in accordance with local regulations, PTC will make Translarna available to nonsense mutation Duchenne muscular dystrophy patients through funded EAP programs.
News For PTCT From The Last 14 Days
Check below for free stories on PTCT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
08:52 EDTPTCTPTC Therapeutics price target raised to $43 from $34 at Roth Capital
Subscribe for More Information
August 12, 2014
09:57 EDTPTCTPTC Therapeutics management to meet with Oppenheimer
Meeting to be held in Toronto on August 18 hosted by Oppenheimer.
August 11, 2014
15:27 EDTPTCTWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
August 7, 2014
14:05 EDTPTCTPTC Therapeutics reports publication of preclinical study results in SMA models
PTC Therapeutics (PTCT) announced that he journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy or SMA. Stuart Peltz, CEO of PTC Therapeutics, said, "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development." Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche (RHHBY), said, "Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA. This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."
07:41 EDTPTCTPTC Therapeutics reports Q2 EPS (86c), consensus (75c)
Reports Q2 revenue $1.68M, consensus $1.71M.
06:48 EDTPTCTPTC Therapeutics files automatic mixed securities shelf

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use